Análogo de cumarina 3-metil-7H-furo[3,2-g]cromen-7-ona, un posible agente antiparquinsoniano

Introduction: Parkinsonu0027s disease (PD) is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease, concomitantly with levodopa or as monotherapy. Several substituted coumarins have showed activity as inhibitors of monoamine oxidase B. Objective: To evaluate the possible anti-parkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models as well as its the inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity. Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamino oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively. Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. In addition, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion: These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent.